Prescription drug expenditures and population demographics

被引:28
作者
Morgan, SG [1 ]
机构
[1] Univ British Columbia, Ctr Hlth Serv & Policy Res, Vancouver, BC V6T 1Z3, Canada
关键词
prescription drugs; expenditures; demographics; British Columbia;
D O I
10.1111/j.1475-6773.2005.00495.x
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objective. To provide detailed demographic profiles of prescription drug utilization and expenditures in order to isolate the impact of demographic change from other factors that affect drug expenditure trends. Data Sources/Study Setting. Demographic information and drug utilization data were extracted for virtually the entire British Columbia (BC) population of 1996 and 2002. All residents had public medical and hospital insurance; however their drug coverage resembled the mix of private and public insurance in the United States. Study Design. A series of research variables were constructed to illustrate profiles of drug expenditures and drug utilization across 96 age/sex strata. Data Collection/Extraction Methods. Drug use and expenditure information was extracted from the BC PharmaNet, a computer network connecting all pharmacies in the province. Principal Findings. Per capita drug expenditures increased at an average annual rate of 10.8 percent between 1996 and 2002. Population aging explained 1.0 points of this annual rate of expenditure growth; the balance was attributable to rising age/sex-specific drug expenditures. Conclusions. Relatively little of the observed increase in drug expenditures in BC could be attributed to demographic change. Most of the expenditure increase stemmed from the age/sex-specific quantity and type of drugs purchased. The sustainability of drug spending therefore depends not on outside forces but on decisions made by policy makers, prescribers, and patients.
引用
收藏
页码:411 / 428
页数:18
相关论文
共 14 条
[1]   AVALANCHE OR GLACIER - HEALTH-CARE AND THE DEMOGRAPHIC RHETORIC [J].
BARER, ML ;
EVANS, RG ;
HERTZMAN, C .
CANADIAN JOURNAL ON AGING-REVUE CANADIENNE DU VIEILLISSEMENT, 1995, 14 (02) :193-224
[2]   The US pharmaceutical industry: Why major growth in times of cost containment? [J].
Berndt, ER .
HEALTH AFFAIRS, 2001, 20 (02) :100-114
[4]   APOCALYPSE NO: Population aging and the future of health care systems [J].
Evans, RG ;
McGrail, KM ;
Morgen, SG ;
Barer, ML ;
Hertzman, C .
CANADIAN JOURNAL ON AGING-REVUE CANADIENNE DU VIEILLISSEMENT, 2001, 20 :160-191
[5]  
FUCHS VR, 1984, MILBANK FUND Q, V62, P143
[6]  
Gerdtham Ulf-G, 2004, Expert Rev Pharmacoecon Outcomes Res, V4, P343, DOI 10.1586/14737167.4.3.343
[7]   Coronary heart disease prevention: insights from modelling incremental cost effectiveness [J].
Marshall, T .
BMJ-BRITISH MEDICAL JOURNAL, 2003, 327 (7426) :1264-1267
[8]   The population's use of pharmaceuticals [J].
Metge, C ;
Black, C ;
Peterson, S ;
Kozyrskyj, AL .
MEDICAL CARE, 1999, 37 (06) :JS42-JS59
[9]   Whither seniors' pharmacare: Lessons from (and for) Canada [J].
Morgan, SG ;
Barer, ML ;
Agnew, JD .
HEALTH AFFAIRS, 2003, 22 (03) :49-59
[10]   Quantifying components of drug expenditure inflation: The British Columbia seniors' drug benefit plan [J].
Morgan, SG .
HEALTH SERVICES RESEARCH, 2002, 37 (05) :1243-1266